AstraZeneca PLC American Depositary Shares (AZN)
AZN Q2 Earnings Meet Estimates, Sales Beat as Key Drugs Outperform
AZN's second-quarter revenues beat on strong drug sales across Oncology and CVRM despite in-line earnings.
AstraZeneca Stock Rises as US, Cancer Drug Growth Lifts Q2 Results
AstraZeneca (AZN) shares are rising in premarket trading Tuesday after the pharma giant beat second-quarter estimates on strong U.S. growth and demand for its cancer drugs.
AstraZeneca maintains outlook as pipeline delivers strong late-stage results
AstraZeneca PLC (LSE:AZN) has reiterated its full-year guidance for 2025, following a robust set of results for the second quarter and first half, and pointed to a series of significant late-stage trial successes across its research and development pipeline. The pharmaceutical group reported total revenue of $14.46 billion for the second quarter, up 12% compared with the same period last year at actual exchange rates, driven by double-digit growth in oncology and biopharmaceuticals.
AstraZeneca beats second-quarter profit expectations, maintains outlook
AstraZeneca beat second-quarter earnings expectations on Tuesday, helped by strong sales of key cancer, heart and kidney disease drugs, but maintained its full-year forecast as pricing pressures and global trade risks remain challenges.
Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for Investors
In the most recent trading session, Astrazeneca (AZN) closed at $72.66, indicating a -1.38% shift from the previous trading day.
Insights Into Astrazeneca (AZN) Q2: Wall Street Projections for Key Metrics
Evaluate the expected performance of Astrazeneca (AZN) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
AstraZeneca announces $50 billion investment in U.S. as Trump's tariffs loom
AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, it said on Monday, the latest big investment by a pharmaceutical company reacting to President Donald Trump's tariff policy.
AZN Commits USD50B to US Manufacturing Expansion Amid Tariff Pressures
AstraZeneca unveils a $50 billion U.S. manufacturing expansion plan, anchored by a Virginia facility to boost drug output and counter tariff headwinds.
AstraZeneca to invest $50B in US to boost drug manufacturing and R&D
AstraZeneca PLC (LSE:AZN) has announced plans to invest $50 billion in the United States by 2030, marking the pharmaceutical giant's largest-ever investment in a single market. The UK-headquartered biopharmaceutical company said the investment will expand its domestic manufacturing and research footprint as it works toward a long-term revenue target of $80 billion annually, with half of that total expected to come from the US market.
5 Things to Know Before the Stock Market Opens
Stock futures are little changed as investors watch for more earnings and trade developments; AstraZeneca (AZN) said it plans to invest $50 billion in U.S. production facilities; Opendoor Technologies (OPEN) shares are on the rise as retail investors continue to pile into the meme stock; and OpenAI and Softbank are reportedly paring back near-term plans for their $500 billion Stargate project. Here's what investors need to know today.
AstraZeneca Plans to Invest $50B in US Manufacturing and Research by 2030
AstraZeneca (AZN) said Tuesday it's planning to invest $50 billion in expanding its manufacturing and research presence in the U.S. by 2030, as worries about President Donald Trump's tariffs loom over the industry.
AstraZeneca to build new Virginia plant as it re-hashes other U.S. investment plans
AstraZeneca, the U.K.-Swedish pharmaceutical giant, on Tuesday announced a plan to invest some $50 billion in the U.S. in a move hailed by the Trump administration — though much of what it is announcing it's already announced before.
